Drug Safety

      Abstract 1718: Immune checkpoint inhibitors (ICI) in pre-existing #SLE
      Compared to non-SLE pts, those with SLE receiving

      Akhil Sood MD, MS AkhilSoodMD

      3 months ago
      Abstract 1718: Immune checkpoint inhibitors (ICI) in pre-existing #SLE Compared to non-SLE pts, those with SLE receiving ICIs had: 🔹 ↑ risk of thrombocytopenia & pancytopenia 🔹 No significant difference in all-cause mortality @RheumNow #ACR25 https://t.co/N1iOvxbsAZ
      IL-5 agents may in fact work for severe EGPA manifestations

      Although severe pt were excluded from enrollment in MANDARA

      Brian Jaros, MD Dr_Brian_MD

      3 months ago
      IL-5 agents may in fact work for severe EGPA manifestations Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients @RheumNow #ACR25 https://t.co/slUpAT9mWo
      ANCA status does not inform IL-5 agent response in EGPA patients

      Terrier et al. analyzed the OLE of MANDARA and compare

      Brian Jaros, MD Dr_Brian_MD

      3 months ago
      ANCA status does not inform IL-5 agent response in EGPA patients Terrier et al. analyzed the OLE of MANDARA and compared ANCA+ and ANCA- subgroups: - similar rates of remission - similar rates of GC withdrawal - comparable relapse rates @RheumNow #ACR25 Abst 1594
      Abstract 1657: Can LLMs track medication history?GPT-4 outperformed most LLMs in identifying TNFi start/stop events and

      Akhil Sood MD, MS AkhilSoodMD

      3 months ago

      Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. đź’Š Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu

      #ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago

      #ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

      #ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airw

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airway features of #EGPA improved with Benralizumab/Mepolizumab. Provides assurance to use more in real-world @RheumNow https://t.co/i78xXojGja
      #ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syn

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago

      #ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

      So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset?

      ALTO study (APIPPRA contin

      David Liew drdavidliew

      3 months ago
      So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6
      Early TNFi treatment leads to

      -Less D2T at 5 yrs
      -More sustained remission at 10yrs
      -Less bDMARD escalation at 5yrs
      -M

      Aurelie Najm AurelieRheumo

      3 months ago
      Early TNFi treatment leads to -Less D2T at 5 yrs -More sustained remission at 10yrs -Less bDMARD escalation at 5yrs -More DMARD free remission at 5yrs and 10 yrs -20% reduction annual healths costs -11 mo delay in ttmt escalation Safety data were not presented #ACR25 https://t.co/jPMGUGPtqP
      SELECT-COMPARE RA UPA vs. ADA

      What do we learn from 7 years data? Not much

      Patients who did well on the first drug, ke

      Aurelie Najm AurelieRheumo

      3 months ago
      SELECT-COMPARE RA UPA vs. ADA What do we learn from 7 years data? Not much Patients who did well on the first drug, keep doing well Patients who required switching for primary failure don't do as well, w/ 26% pts reaching DAS remission in UPA + MTX vs. 16% in ADA + MTX gp No https://t.co/JLUTRZuZOm
      Belimumab Before or After Immunosuppressant
      3 months ago
      In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, eithe

      David Liew drdavidliew

      3 months ago
      In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX
      SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data:

      safety profiles very similar,

      David Liew drdavidliew

      3 months ago
      SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data: safety profiles very similar, except for: - zoster - CK rise - lymphopenia - hepatic disorder In the general RA population, no new JAKi safety signals #ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa
      Start strong, stay strong.

      With early anti-TNF induction (vs csDMARD T2T)
      - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11,

      Jiha Lee JihaRheum

      3 months ago
      Start strong, stay strong. With early anti-TNF induction (vs csDMARD T2T) - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11, p=0.03) Drug-free remission 13% vs 6% (p=0.049) - At 10 yrs: more sustained remission (62% vs 45%) & fewer multi-MoA failures. @RheumNow #ACR25 Abstract #1677
      What is the secret of a VNS RCT that works in RA?
      => Implant the device!

      RESET-RA RCT Sham controlled 3mo
      Then open

      Aurelie Najm AurelieRheumo

      3 months ago
      What is the secret of a VNS RCT that works in RA? => Implant the device! RESET-RA RCT Sham controlled 3mo Then open label in active arm for 66mo 40% pts IR to >=3 bioDMARDs ACR 20 3 mo 42% vs. 19% CDAI LDA 27% vs. 11% 82% TNF IR pt had no change in treatment over 12mo 99% https://t.co/lfxa4YXUB4

      Podcasts

      • ACR 2025 Daily Podcasts Day2d

      Catch up on Conference Podcasts

      ×